美国 · SEC FORM 4
Bicara Therapeutics Inc.
BCAX · Nasdaq · CIK 0002023658 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
31 同一窗口内观察到的 Form 4 交易行
20 sales · 11 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-02-26 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -19.9%
- 3M
- -36.5%
- 6M
- -26.4%
- 12M
- +1.8%
波动率与流动性
- 波动率
- 73.7%
- Beta
- —
- 平均每日成交额
- USD 11.7M
估值
- 市值
- USD 1.2B
- P/E
- —
基本面
- 利润率
- —
- ROE
- -34.4%
- 细分行业
- Biotechnology
市场数据
价格数据截至:2026-10-15 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-06 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 10,693,490
- 上期报告
- 11,191,724
- 日均成交量
- 753,208
- 回补天数
- 14.2
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 300,000 | USD 16.00 | USD 4,800,000 | SEC 申报 ↗ |
| 2024-09-17 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt V, L.P.; Deerfield Private Design Fund V, L.P.; Flynn James E | 买入 (P) | Common Stock | 35,000 | USD 18.00 | USD 630,000 | SEC 申报 ↗ |
| 2024-09-16 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,833,000 | USD 18.00 | USD 32,994,000 | SEC 申报 ↗ |
Form 4 申报证据
105 transaction lines in the latest 365-day window; 158 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 17,500 | USD 22.90 | USD 400,747 | SEC 申报 ↗ |
| 2026-09-08 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 17,500 | USD 3.79 | USD 66,325 | SEC 申报 ↗ |
| 2026-08-10 | Mazumdar Claire | 卖出 (S) | Common Stock | 10,000 | USD 27.98 | USD 279,800 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 17,500 | USD 22.90 | USD 400,747 | SEC 申报 ↗ |
| 2026-09-08 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 17,500 | USD 3.79 | USD 66,325 | SEC 申报 ↗ |
| 2026-08-10 | Mazumdar Claire | 卖出 (S) | Common Stock | 10,000 | USD 27.98 | USD 279,800 | SEC 申报 ↗ |
| 2026-08-10 | Mazumdar Claire | 期权行权/转换 (M) | Common Stock | 10,000 | USD 3.79 | USD 37,900 | SEC 申报 ↗ |
| 2026-08-10 | Hyep Ivan | 卖出 (S) | Common Stock | 12,500 | USD 27.97 | USD 349,625 | SEC 申报 ↗ |
| 2026-08-10 | Hyep Ivan | 期权行权/转换 (M) | Common Stock | 12,500 | USD 3.79 | USD 47,375 | SEC 申报 ↗ |
| 2026-08-10 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 18,750 | USD 27.98 | USD 524,625 | SEC 申报 ↗ |
| 2026-08-10 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 18,750 | USD 3.79 | USD 71,062 | SEC 申报 ↗ |
| 2026-07-10 | Mazumdar Claire | 卖出 (S) | Common Stock | 10,000 | USD 28.42 | USD 284,235 | SEC 申报 ↗ |
| 2026-07-10 | Mazumdar Claire | 期权行权/转换 (M) | Common Stock | 10,000 | USD 3.79 | USD 37,900 | SEC 申报 ↗ |
| 2026-07-09 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 536 | USD 29.00 | USD 15,544 | SEC 申报 ↗ |
| 2026-07-08 | Hyep Ivan | 卖出 (S) | Common Stock | 28,000 | USD 28.84 | USD 807,603 | SEC 申报 ↗ |
| 2026-07-08 | Hyep Ivan | 期权行权/转换 (M) | Common Stock | 12,500 | USD 3.79 | USD 47,375 | SEC 申报 ↗ |
| 2026-07-08 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 28,214 | USD 28.98 | USD 817,622 | SEC 申报 ↗ |
| 2026-07-08 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 18,750 | USD 3.79 | USD 71,062 | SEC 申报 ↗ |
| 2026-05-21 | Hyep Ivan | 卖出 (S) | Common Stock | 9,200 | USD 20.42 | USD 187,864 | SEC 申报 ↗ |
| 2026-05-21 | Hyep Ivan | 期权行权/转换 (M) | Common Stock | 9,200 | USD 3.79 | USD 34,868 | SEC 申报 ↗ |
| 2026-05-18 | Mazumdar Claire | 卖出 (S) | Common Stock | 15,000 | USD 20.04 | USD 300,561 | SEC 申报 ↗ |
| 2026-05-18 | Mazumdar Claire | 期权行权/转换 (M) | Common Stock | 15,000 | USD 3.79 | USD 56,850 | SEC 申报 ↗ |
| 2026-05-15 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 12,500 | USD 20.29 | USD 253,625 | SEC 申报 ↗ |
| 2026-05-15 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 8,000 | USD 3.79 | USD 30,320 | SEC 申报 ↗ |
| 2026-04-27 | Raben David | 卖出 (S) | Common Stock | 5,500 | USD 22.88 | USD 125,840 | SEC 申报 ↗ |
| 2026-04-27 | Raben David | 期权行权/转换 (M) | Common Stock | 5,500 | USD 3.79 | USD 20,845 | SEC 申报 ↗ |
| 2026-04-21 | Hyep Ivan | 卖出 (S) | Common Stock | 9,200 | USD 23.00 | USD 211,600 | SEC 申报 ↗ |
| 2026-04-21 | Hyep Ivan | 期权行权/转换 (M) | Common Stock | 9,200 | USD 3.79 | USD 34,868 | SEC 申报 ↗ |
| 2026-04-20 | Mazumdar Claire | 卖出 (S) | Common Stock | 15,000 | USD 23.61 | USD 354,150 | SEC 申报 ↗ |
| 2026-04-20 | Mazumdar Claire | 期权行权/转换 (M) | Common Stock | 15,000 | USD 3.79 | USD 56,850 | SEC 申报 ↗ |
| 2026-04-16 | Mazumdar Claire | 期权行权/转换 (M) | Common Stock | 22,760 | USD 4.54 | USD 103,360 | SEC 申报 ↗ |
| 2026-04-15 | Cohlhepp Ryan | 卖出 (S) | Common Stock | 12,500 | USD 23.01 | USD 287,625 | SEC 申报 ↗ |
| 2026-04-15 | Cohlhepp Ryan | 期权行权/转换 (M) | Common Stock | 8,000 | USD 3.79 | USD 30,320 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | BCAX |
| CIK | 0002023658 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 158 transaction lines from 2024-09-16 to 2026-09-08 4 P purchase lines · 76 S sale lines · 78 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.